ESA Apprise Oncology Program
Amgen has implemented a risk evaluation and mitigation strategy involving the use of erythropoiesis stimulating agents (ESAs) in oncology patients. It requires that all patients who are given ESAs get an informed consent regarding the risk of increased progression of some cancers with the use of ESAs. It is required that all physicians writing for these medications enroll in the program by February 16, 2011. You will be asked yearly whether you have enrolled but the enrollment is good for 3 years.
We will be monitoring the use of ESA’s via a Discern alert and confirming that physicians writing for this have enrolled in the program. Failure to follow this could lead to the facility’s exclusion from the use of this medication. To learn more, please click here.